How to Manage Paper Assessments in eCOA Trials: Without Delays or Transcription Risk
A YPrime Blog By:
Aubrey Verna,
Senior Product Director,
YPrime
Electronic clinical outcome assessments (eCOA) are a foundational component of clinical trial execution. They enable structured data capture, enforce protocol-defined logic, support proactive oversight, and provide sponsors with faster access to high-quality patient data. When implemented effectively, eCOA reduces operational complexity and strengthens confidence in trial outcomes.
The purpose of eCOA is to move trials away from paper. Still, even in well-designed studies, there are limited situations where electronic entry is not possible. In those cases, paper assessments in eCOA trials may occur as a contingency. The real issue is not the presence of paper, but how paper data is handled once it is collected.
Too often, paper assessments trigger outdated workflows that rely on external transcription, manual review, and delayed database entry. These processes introduce transcription risk, slow data migration timelines, and weaken confidence in the data.
A more controlled approach treats paper as a temporary exception while holding it to the same standards applied to electronic data, ensuring continuity without compromising data integrity or oversight.
Paper assessments may be unavoidable, but outdated transcription isn’t. YPrime enables site-entered data within a controlled eCOA workflow, preserving GCP-aligned data integrity.
Why Paper Assessments Create Risk in eCOA Trials
When paper source data is handled outside the eCOA environment, multiple risks emerge. Transcription is often performed by individuals who were not present during the assessment. Validation rules and conditional logic built into the eCOA system may not be applied consistently. Each handoff increases the likelihood of error.
These issues are not theoretical. They are common sources of late-stage queries, reconciliation effort, and inspection findings. Paper use should be minimized, but when unavoidable, it must be managed with the same rigor as electronic entry.
Treating Paper as a GCP-Aligned Contingency in eCOA Trials
Good Clinical Practice allows paper source data when it is completed appropriately and retained under investigator control. At the core of this allowance is data integrity, which GCP defines explicitly. As stated in the ICH E6(R3), Good Clinical Practice Guidance, “Data integrity includes the degree to which data fulfill key criteria of being attributable, legible, contemporaneous, original, accurate, complete, secure and reliable such that data are fit for purpose.” These expectations apply regardless of whether data is collected electronically or on paper.
The Guidance also places responsibility for maintaining this integrity with the investigator, stating that “The investigator/institution should maintain adequate source records that include pertinent observations on each of the trial participants under their responsibility.” Source records must be attributable, legible, contemporaneous, original, accurate, and complete, and any changes “should be traceable, should not obscure the original entry, and should be explained if necessary (via an audit trail).” This reinforces that paper source documents should remain at the site, where data integrity can be preserved.
GCP also makes clear that investigators are responsible for the quality of data once it is entered into data acquisition systems. The guidance states that “The investigator should ensure the accuracy, completeness, legibility, and timeliness of the data reported to the sponsor in the data acquisition tools completed by the investigator site.” Investigators are further expected to “review and endorse the reported data at important milestones agreed upon with the sponsor (e.g., interim analysis).”
Taken together, these principles support an approach that keeps paper source documents at the site while allowing data to be entered directly into the eCOA system through defined, auditable workflows. By minimizing transcription steps and enforcing consistent controls, this model aligns operational execution with GCP intent and ensures paper remains a true contingency rather than a parallel data pathway.
Site-Entered Paper Data Using Automated DCF (Data Change Form)
Speed of data entry alone does not ensure data quality. To preserve data integrity across a study, paper-entered data must be subject to the same rules as electronically captured data.
A controlled paper entry workflow enforces the same validations, required fields, and conditional logic defined in the eCOA assessment. Entries that would not be permitted electronically cannot be entered through paper transcription. By maintaining this consistency at the point of entry, studies reduce downstream queries, limit reconciliation effort, and simplify both interim and final analysis.
Operational Benefits of Automated DCFs for Sponsors and Sites
When considering how to manage paper assessments or data corrections within an eCOA study, sponsors and sites must balance data integrity, oversight, and operational efficiency. Automated Data Change Forms provide a structured way to bring paper-entered data into the eCOA system without introducing unnecessary handoffs or compromising control.
For sites, direct data entry reduces administrative burden and eliminates the need for external document handling. The individuals closest to the assessment retain ownership of the data, while defined workflows support timely entry, review, and endorsement.
For sponsors, faster access to complete datasets enables earlier insight generation, more proactive oversight, and stronger inspection readiness. Fewer manual handoffs reduce transcription risk and limit downstream reconciliation effort.
Reducing Paper Reliance Without Breaking Clinical Trial Continuity
eCOA is designed to strengthen data quality, enforce protocol-defined logic, and accelerate trial execution by giving sponsors and sites faster access to reliable participant data. Reducing reliance on paper is a natural outcome of this structure, but the true objective is protecting data integrity while keeping trials moving.
When paper assessments occur as a contingency, the risk is not the paper itself, but outdated data change and transcription processes that introduce delay, error, and administrative burden. Manual workflows slow timelines, fragment oversight, and pull site staff away from participant care, impacting clinical research.
YPrime’s Automated Data Change Form was built to address this challenge directly. By enabling sites to enter and manage paper-derived data within the eCOA platform using configurable workflows, robust validations, and comprehensive audit trails, YPrime removes unnecessary bottlenecks from the data lifecycle. Data changes that once took days or weeks can be completed in minutes, without sacrificing control, traceability, or regulatory alignment.
This approach empowers sites to retain ownership of their data while reducing administrative overhead. For sponsors, it delivers faster access to complete, inspection-ready datasets that support earlier insight generation and more proactive oversight.
About YPrime eCOA Automated DCF
When paper assessments are unavoidable, they must enter the system quickly, accurately, and under full control. That helps protect data integrity and mantains trial momentum. Click here to learn more about YPrime’s Automated DCF, or visit www.yprime.com/ecoa to explore how YPrime eCOA can improve data integrity in your clinical trials.
Source – https://database.ich.org/sites/default/files/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf
Frequently Asked Questions on Paper vs. eCOA
Paper assessments should be used only when electronic entry is not possible. When unavoidable, sites should enter paper data directly into the eCOA system using controlled workflows that preserve validation rules, audit trails, and data integrity.
The clinical trial site should enter paper data into the eCOA system. This maintains source ownership, reduces transcription risk, and eliminates delays associated with vendor-based data entry.
Yes. Paper-entered data should follow the same validation rules, conditional logic, and navigational flows as electronically captured data to ensure consistency across the dataset.
Site-entered paper data improves eCOA oversight by reducing transcription errors, shortening data availability timelines, and maintaining clear audit trails that support proactive monitoring and inspection readiness.
Vendor transcription introduces multiple handoffs, increases the risk of data entry errors, and delays sponsor access to complete datasets. Site-entered workflows reduce these risks by keeping data closer to the source.
Clinical trial sponsors should allow paper assessments only as a contingency when electronic data capture is not possible. Paper should not operate as a parallel system but as a controlled exception within an eCOA-driven study.
Check Out More eCOA Resources
about trial design, data capture, operational efficiencies, and, ultimately, solving for certainty in clinical research.
